Actinium Pharmaceuticals, Inc. — Director's Dealing 2015

May 22, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2015-05-07

Reporting Person: DAVE KAUSHIK J (Director, President, CEO and Interim CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-07	Common stock	F	7083	$2.45	Disposed	57083	Direct
2015-05-07	Common stock	D	27501	$2.45	Disposed	57083	Direct
2015-05-07	Common stock	F	16000	$2.45	Disposed	73083	Direct
2015-05-07	Common Stock	D	68000	$2.45	Disposed	73083	Direct
2015-05-07	Common stock	F	12500	$2.45	Disposed	85583	Direct
2015-05-07	Common stock	D	25000	$2.45	Disposed	85583	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-05-07	Options to purchase common stock	$2.52	A	82128	Acquired	2025-05-07	Common stock (82128)	Direct
2015-05-07	Options to purchase common stock	$2.52	A	63063	Acquired	2025-05-07	Common stock (63063)	Direct

Footnotes

F1: Recipient was granted 41,667 shares of restricted common stock on 1/10/14. As of May 7, 2015, 14,166 shares were vested. Company withheld 7,083 shares to pay tax obligations of award recipient on vested shares. The remaining 27,501 unvested shares of restricted stock were cancelled and a new award of 32,869 options exercisable for shares of common stock were granted to the recipient.

F2: 11,667 shares vested on 1/10/15 and the share price was $5.17; 833 shares vested on 2/10/15 and the share price was $3.52; 833 shares vested on 3/10/15 and the share price was $2.95; and 833 shares vested on 4/10/15 and the share price was $2.96.

F3: Recipient was granted 100,000 shares of restricted common stock on 2/21/14. As of May 7, 2015, 32,000 shares were vested. Company withheld 16,000 shares to pay tax obligations of award recipient on vested shares. The remaining 68,000 unvested shares of restricted stock were cancelled and a new award of 82,128 options exercisable for shares of common stock were granted to the recipient.

F4: 28,000 shares vested on 2/21/15 and the share price was 3.51; 2,000 shares vested on 3/21/15 and the share price was $2.87; and 2,000 shares vested on 4/21/15 and the share price was $3.08.

F5: Recipient was granted 100,000 shares of restricted common stock on 9/16/13, of which 50,000 shares vested on 9/16/14. As of May 7, 2015, an additional 25,000 shares were vested in 2015. Company withheld 12,500 shares to pay tax obligations of award recipient on 2015 vested shares. The remaining 25,000 unvested shares of restricted stock were cancelled and a new award of 30,194 options exercisable for shares of common stock were granted to the recipient.

F6: Options vest based on certain miles stones: Filing IND (50%); First Patient in (10%); Hiring of VP-Mfg or other competent person and training so that person is capable of producing Iomab-B (25%); Completion of Actimab-A 1 step labeling (10%); and VP Manufacturing or other competent person to handle manufacturing and logistics of Actimab-A (5%).